Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells

Biochemical Pharmacology

Volumn 58, Issue 3, 1999, Pages 477-486

  Grem, Jean L ^a,b   Nguyen, Diana ^a,b   Monahan, Brian P ^a   Kao, Vivian ^a,b   Geoffroy, Francois J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Bcl 2; DNA damage; Drug interactions; Fluorouracil; p21; p53; Taxanes

Indexed keywords

DNA FRAGMENT; DOUBLE STRANDED DNA; FLUOROURACIL; PACLITAXEL; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; RNA; THYMIDYLATE SYNTHASE; TRITIUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA, NEOPLASM; DRUG ADMINISTRATION SCHEDULE; DRUG ANTAGONISM; FLUOROURACIL; HUMANS; PACLITAXEL; RNA, NEOPLASM; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032974159     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00099-4     Document Type: Article

References (35)

1. Manfredi JJ and Horwitz SB, Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83-125, 1984.
2. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ and Yang CP, Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monogr 15: 55-61, 1993.
3. 1 phase by interfering with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 54: 4355-4361, 1994.
4. Diaz JF and Andreu JM, Assembly of purified GDP-tubulin into microtubules induced by Taxol and taxotere: Reversibility, ligand stoichiometry and competition. Biochemistry 23: 2747-2755, 1993.
5. Jordan MA, Toso RJ, Thrower D and Wilson L, Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556, 1993.
6. Huizing MT, Sewberath Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CHN, Vermorken JB, Pinedo HM and Beijnen JH, Taxanes: A new class of antitumor agents. Cancer Invest 13: 381-404, 1995.
7. Rowinsky EK and Donehower RC, Antimicrotubule agents. In: Cancer Chemotherapy and Biotherapy. Principles and Practice (Eds. Chabner BA and Longo DL), pp. 275-286. Lippincott-Raven, Philadelphia, 1996.
8. Grem JL, 5-Fluorinated pyrimidines. In: Cancer Chemotherapy and Biotherapy. Principles and Practice (Eds. Chabner BA and Longo DL), pp. 149-210. Lippincott-Raven, Philadelphia, 1996.
9. Parker RJ, Dabholkar MD, Lee KB, Bostick-Bruton F and Reed E, Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr 15: 83-88, 1993.
10. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornbluth DR, Hendricks CB and Donehower RC, Sequences of taxol and cisplatin: A phase I and pharmacologie study. J Clin Oncol 9: 1692-1703, 1991.
11. Rowinsky EK, Citardi MJ, Noe DA and Donehower RC, Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119: 727-733, 1993.
12. Kennedy MJ, Zahurak ML, Donehower RC, Noe D, Grochow LB, Sartorius S, Chen TL, Bowling K, Duerr M and Rowinsky EK, Sequence-dependent hematologie toxicity associated with the 3-hour paclitaxel-cyclophosphamide doublet. Clin Cancer Res 4: 349-356, 1998.
13. Holmes FA, Madden TL, Newman RA, Balero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J and Hortobagyi GN, Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713-2721, 1996.
14. Grem JL and Fischer PH, Alteration of fluorouracil metabolism in human colon cancer cells with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6191-6199, 1986.
15. Geoffroy F, Allegra CJ and Grem JL, Enhanced cytotoxicity with interleukin-1 and 5-fluorouracil in HCT 116 colon cancer cells. Oncol Res 6: 581-591, 1994.
16. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D and Jolivet J, Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260: 9720-9726, 1985.
17. Ren QF, Van Groeningen CJ, Geoffroy F, Allegra CJ, Johnston PG and Grem JL, Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells. Oncol Res 9: 77-88, 1997.
18. Grem JL, Politi PM, Berg SL, Benchekroun NM, Patel M, Balis FM, Sinha BK, Dahut W and Allegra CJ, Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem Pharmacol 51: 1649-1659, 1996.
19. Miller SA, Dykes DD and Polesky HF, A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988.
20. Haldar S, Chintapalli J and Croce CM, Taxol-induced bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
21. Haldar S, Jena N and Croce CM, Inactivation of Bcl-2 by phosphorylation, Proc Natl Acad Sci USA 92: 4507-4511, 1995.
22. Ayusawa D, Arai H, Wataya Y and Seno T, A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse FM3A cells. Mutat Res 200: 221-230, 1988.
23. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR and Sikorska M, Apoptotic death in epithelial cells: Cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993.
24. Canman CE, Tang HY, Normolle DP, Lawrence TS and Maybaum J, Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanisms of resistance and cytotoxicity. Proc Natl Acad Sci USA 89: 10474-10478, 1992.
25. James JS, Basnakian AG and Miller BJ, In vitro folate deficiency induces deoxynucleotide pool imbalance, apoptosis and mutagenesis in Chinese hamster ovary cells. Cancer Res 54: 5075-5080, 1994.
26. Grem JL, Geoffroy F, Politi P, Cuddy D, Ross DD, Nguyen D and Allegra CJ, Determinants of sensitivity to 1-β-D-arabinofuranosylcytosine in human colon carcinoma cell lines. Mol Pharmacol 48: 305-315, 1995.
27. Kano Y, Akutsu M, Tsunoda S, Andro J, Matsui J, Suzuki K, Ikeda T, Inoue Y and Adachi KI, Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 74: 704-710, 1996.
28. Johnson KR, Wang L, Miller MC III, Willingham MC and Fan W, 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells. Clin Cancer Res 3: 1739-1745, 1997.
29. cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5: 1041-1050, 1994.
30. Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y, Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-568, 1993.
31. Frey CM, Role of modelling in joint action studies. J Natl Cancer Inst 86: 1493-1495, 1994.
32. Chou T-C, Motzer RJ, Tong Y and Bosl GJ, Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994.
33. Hahn SM, Liebmann JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB and Kaufman D, Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro. Cancer 72: 2705-2711, 1993.
34. Gianni L, Munzone E, Capri G, Fulfara F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P and Bonadonna G, Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995.
35. Takimoto CH, Morrison GB, Frame JN, Liang MD, Nakashima R, Lieberman R, Hamilton JM, Allegra CJ and Grem JL, A Phase I and pharmacokinetic trial of paclitaxel and 5-fluorouracil plus leucovorin in patients with solid tumors. Proc Am Soc Clin Oncol 14: 471, 1995.